Gossamer Bio receives Nasdaq minimum bid deficiency; cure period to Nov 18, 2024

Gossamer Bio, Inc.

Nasdaq notice on May 22, 2024; stock below $1.00 for 30 consecutive business days through May 21.
Company has 180 calendar days, until November 18, 2024, to regain compliance.
To cure, closing bid must be at least $1.00 for ten consecutive business days.
If not cured, may transfer to Nasdaq Capital Market for additional 180 days or face delisting.
Company may consider a reverse stock split to address the deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.